Mới nhất

  • Huawei phát hành Sách trắng NetX 2025

    Tại cuộc họp báo trực tuyến của Huawei với giới phân tích và truyền thông trước thềm Hội nghị Di động Thế giới MWC Thượng Hải 2021, Peng Song, Chủ tịch Bộ phận Kinh doanh Giải pháp và Marketing Mạng của Huawei đã có bài phát biểu quan trọng với tiêu đề "NetX 2025: Con đường dẫn đến mạng lưới tương lai". Trong bài phát biểu này, ông Peng đã công bố việc phát hành Sách trắng NetX 2025, trong đó bao
  • Double Ace launches crypto super-wallet that pays up to 14% APY on assets

    Double Ace (DAA) is a Fintech company that utilises the power of blockchain, AI, and Big Data to provide instant online financial services to individuals. The service DAA provides encompasses consumer finance, personal credit, micro loan, crypto loan, and more.
  • Gemini hỗ trợ Endotech.IO để tự động hóa tiền điện tử thể chế

    EndoTech đã trở thành một tổ chức đáng tin cậy cung cấp các chiến lược tự động hóa giao dịch tiền điện tử.
  • Bitcoin S (BTCS)

    The Bitcoin S (BTCS) transactionchain will integrate the value of public chain to build a global value transfer network. The CBNData data report shows that among the 120 annual consumer buzzwords in the five years from 2016 to 2020, blockchain ranks among the top. Recently, the BTCS transactionchain wallet has attracted the attention of many capital and media in the circle with its fast, safe tran
  • BYD Wins the Largest Pure-Electric Bus Order outside of China

    Bogotá, Colombia - BYD is proud to announce that it has exclusively won cumulative orders to supply 1,002-unit pure-electric buses to the capital of Colombia, Bogotá. This tender was open to all bus technologies, yet BYD won the trust and cooperation of its partners in the fiercely competitive bidding process thanks to its cutting-edge technologies, products and services. This is the largest order
  • Nền tảng MagniPay hướng tới mục tiêu cách mạng hóa và đổi mới thương mại điện tử thời đại hiện đại nhờ tận dụng blockchain và DeFi

    Dự án MagniPay của New Eye Holding Group đã ra mắt nền tảng chạy trên blockchain của mình, hướng tới mục tiêu tạo nên cuộc mạng hóa trong lĩnh vực thương mại điện tử thời đại hiện đại nhờ tận dụng công nghệ blockchain và DeFi.
  • Dab the 5G Era with the Perfume of Books and Fragrance of Ink — allow full rein to a better life with Hisense A7

    On Dec 22nd, Hisense’s new reading flagship cellphone A7 series was officially launched. This series is the continuation of the characteristics of Hisense A series' most typical ink screen design, namely e-ink screen, a kind of screen that uses electronic ink, which is also known as e-paper displays. This is the world's first 5G cellphone equipped with an ink screen, marking the official arrival o
  • THE 9 th RESIDENCE | NEWERA DESIGN

    THE 9 th RESIDENCE "Break the cocoon and become a butterfly"Full record
  • Great News: a Special Drug from China for the treatment of novel coronavirus

    Duan Zhitang (Beijing) International Pharmaceutical Technology Development Co., Ltd. was founded in June 2009, the company has been committed to the inheritance and promotion of traditional Chinese medicine culture, focusing on the development and application of court secret recipe antiviral products, we have achieved a number of scientific and technological achievements in the field of antivirus,
  • The 2020 OCS to take new forms through upgrading

    The 2020 Convention on Exchange of Overseas Talents and the 22nd Guangzhou Convention of Overseas Chinese Scholars in Science and Technology (hereinafter referred to as the 2020 OCS) will be held from December 18 to 19 in Guangzhou, co-hosted by the Ministry of Education, Western Returned Scholars Association and Guangzhou Municipal Government and coordinated jointly by 29 cities including Beijing

Liên kết thân thiện

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

05-22    

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


Tuyên bố miễn trừ trách nhiệm: Bài viết này được sao chép từ các phương tiện khác. Mục đích của việc in lại là để truyền tải thêm thông tin. Điều đó không có nghĩa là trang web này đồng ý với quan điểm của nó và chịu trách nhiệm về tính xác thực của nó và không chịu bất kỳ trách nhiệm pháp lý nào. Tất cả tài nguyên trên trang web này được thu thập trên Internet. Mục đích chia sẻ chỉ dành cho việc học và tham khảo của mọi người. Nếu có vi phạm bản quyền hoặc sở hữu trí tuệ, vui lòng để lại tin nhắn cho chúng tôi.
Về đầu trang
© Bản quyền 2009-2020 Việt nam hàng ngày      Liên lạc với chúng tôi   SiteMap